THD NewsDesk, New Delhi: The United Kingdom has become the leading nation to approve Covid-19 vaccine. However, India remains to wait for the Oxford-AstraZeneca shot along with some other Indian competitors as its pick to address Covid-19.
The Pfizer-BioNTech Covid-19 vaccine is not feasible for India at the moment, and its necessity for ultra-cold temperature — minus 70 degree Celsius (minus 94 degrees Fahrenheit) — for storage is a grave obstacle as the vaccine will require to be disseminated in remote areas, and even urban centres lack such amenities.
“Where are the supplies? Many western countries have already booked stocks, including the UK which has apparently ordered enough for its people. So, obviously, these countries will get it first,” an official said.
He added while the state is in discussions with all corporations, it is likely that vaccine being produced by Oxford-AstraZeneca or Bharat Biotech will finish trials and attempt to get the endorsement at an early date.
The administration is eagerly following progress in Oxford-AstraZeneca applicant for which Serum Institute is the local partner and has said it will appeal for emergency use sanction in the next few days.
Bharat Biotech’s Covaxin, which is in Phase 3 of human trials, is also expected to get usage permission shortly as it is on an accessible platform and the trials so far have been constant, the official said.